Tyvaso
Total Payments
$862,845
Transactions
323
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $862,845 | 323 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $862,800 | 322 | 100.0% |
| Food and Beverage | $44.49 | 1 | 0.0% |
Payments by Type
Research
$862,800
322 transactions
General
$44.49
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | United Therapeutics Corporation | $862,800 | 0 |
Top Doctors Receiving Payments for Tyvaso
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hershey, PA | $862,800 | 322 |
| , M.D | Internal Medicine | Louisville, KY | $44.49 | 1 |
Ad
Manufacturing Companies
- United Therapeutics Corporation $862,845
Product Information
- Type Drug
- Total Payments $862,845
- Total Doctors 1
- Transactions 323
About Tyvaso
Tyvaso is a drug associated with $862,845 in payments to 1 healthcare providers, recorded across 323 transactions in the CMS Open Payments database. The primary manufacturer is United Therapeutics Corporation.
Payment data is available from 2024 to 2024. In 2024, $862,845 was paid across 323 transactions to 1 doctors.
The most common payment nature for Tyvaso is "Unspecified" ($862,800, 100.0% of total).
Tyvaso is associated with 1 research study, including "A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)" ($862,800).